Humacyte Inc. (NASDAQ: HUMA) announced the pricing of an underwritten public offering of 47.6 million shares of common stock at $1.05 per share, with expected gross proceeds of approximately $50 million before underwriting discounts, commissions and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 7.1 million shares at the public offering price.
The offering is expected to close on or about June 12, 2026, subject to customary closing conditions. Humacyte intends to use the net proceeds to support commercialization of Symvess, its first FDA-approved product, which began U.S. commercial launch in the first quarter of 2025. Symvess is a bioengineered human tissue for extremity vascular trauma.
Additionally, the funds will advance a planned Biologics License Application supplement filing for a hemodialysis indication, fund development of pipeline candidates, and provide working capital for general corporate purposes. This capital raise is critical for Humacyte as it scales up commercial operations and expands its product pipeline.
Barclays, BTIG and Titan Partners, a division of American Capital Partners, are serving as joint book-running managers for the offering. For more details, visit the full press release at https://ibn.fm/k6T1b.
Humacyte is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale. The company is pioneering off-the-shelf, bioengineered human tissues and advanced tissue constructs with the goal of improving patient lives and transforming medicine.
For uses other than FDA approval in extremity vascular trauma, the acellular tissue engineered vessel (ATEV) remains investigational. Further information about Humacyte is available at https://humacyte.com/.
